Sector News

Shake-up at AstraZeneca as two immuno-oncology leaders leave

January 6, 2015
Life sciences
(Reuters) – AstraZeneca has appointed a new leader for its all-important immuno-oncology drug development operation after the departure of the previous head for personal reasons, the British-based drugmaker said on Monday.
 
Rachel Humphrey left the company at the end November and was replaced last month by Robert Iannone, a member of the global medicines development team, a spokeswoman said in response to inquiries. Her departure was not announced at the time.
 
Humphrey’s exit coincides with the loss of another leader in immuno-oncology, albeit from a different part of the firm. Peter Emtage, who was involved in early research at AstraZeneca’s unit MedImmune, was appointed to a senior position at biotech company Intrexon on Dec. 4.
 
AstraZeneca said the two departures were a coincidence and the company’s work in immuno-oncology was proceeding at full steam, with no problems with any programmes. “It’s business as usual,” the spokeswoman said.
 
The drugmaker, which saw off a $118 billion takeover attempt by Pfizer last year, is banking on new cancer medicines to help revive its fortunes.
 
It is also hoping for an imminent boost to its heart drug Brilinta from results of a clinical trial – known as PEGASUS – assessing the medicine’s use in patients who experienced a heart attack 1-3 years ago. That group could more than double the number of patients eligible for Brilinta. (Reporting by Ben Hirschler; Editing by Pravin Char)

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach